ASX: BUB Bubs Australia



4th ANNUAL DOING BUSINESS IN CHINA INVESTOR CONFERENCE



29 October 2020

Jennifer Hawkins Bubs Global Brand Ambassador



DISCLAIMER

This investor presentation (Presentation) is dated 29 October 2020 and has been prepared by Bubs Australia Limited (ACN 060 094 742) (Bubs or the Company). The material in this Presentation is general background information about Bubs' activities current at the date of the Presentation. It has been prepared based on information available to it, including information from third parties, and has not been independently verified nor does it purport to be complete. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information or opinions contained in this Presentation.

This Presentation does not constitute investment or financial product advice (nor taxation, accounting or legal advice) and does not take into account the investment objectives, financial situation or needs of any particular investor. It is not a prospectus, product disclosure statement or other disclosure or offering document under Australian law or any other law. This Presentation is not and should not be considered a recommendation to, or offer or an invitation to acquire shares in Bubs, nor does not and will not form the basis of any contract or commitment for the acquisition of shares. The distribution of this Presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions.

This Presentation contains certain 'forward-looking statements'. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Bubs, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Bubs' business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Bubs, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward-looking statements are based on information available to Bubs as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), none of Bubs, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

Certain non-IFRS financial information has been included to assist in the making appropriate comparisons with prior periods to assess the operating performance of the business. Bubs uses these measures to assess the performance of the business and believes that the information is useful to investors. Non-IRFS information has not been subject to auditor review.

Unless otherwise stated, all dollar values are in Australian dollars (\$ or A\$). A number of figures, amounts, percentages, estimates, calculations of value and fractions in this Presentation are subject to the effect of rounding.



Growing Generation Joy™













Creating new generations of happy, healthy böbs

GOODNESS

We believe in wholesome, healthy food and a positive approach to life.

HONESTY

We believe in 100% transparency, this is 'clean' food from a brand you trust.

VERY BEST

We believe in being thorough and uncompromising, sticking to our ethics no matter what.

PLAYFULNESS

We believe in the joy of family time, the pleasure of sharing happy moments and being together.

CONTENTS PAGE

<u>China Focus</u>

Financial Performance	07
Business Overview	10
Strategic Focus	22
Growth Pathway	30



"If chess is about the decisive battle, wei qi is about the protracted campaign. The chess player aims for total victory. The wei qi player seeks relative advantage."

— Henry Kissinger



FINANCIAL **PERFORMANCE**






FY20 GROUP FINANCIAL PERFORMANCE

Strong growth across core products and all regions.




GROUP GROSS REVENUE

Continued strong growth year on year.




REGIONAL CHANNEL MIX

Increasing market diversification.



BALANCED PRODUCT MIX

Optimising portfolio mix to maximise profitability.






FUELLED BY STRONG CHINA DEMAND

China remains catalyst for global growth.



TOTAL CHINA DIRECT EXPORT GROWTH



- Growth driven by demand for Bubs® Goat Infant Formula portfolio.
- Supported by expansion into Mother & Baby Stores General Trade with China Label products.
- Scale in China provides platform for global expansion.




BUSINESS OVERVIEW




OUR UNIQUE VALUE PROPOSITION

360° integrated business model, combining the best of an ingredient and manufacturing business, together with a brand-led and consumer focused portfolio driven business.



CAN ONLY BE ACQUIRED WITH EXPERIENCE **OVER THE LONG-TERM**

We are now entering the third phase of the Bubs Journey, with rapid global expansion built on brand trust, invaluable knowledge and intellectual property.





OPTIMISING **SUPPLY CHAIN**

Bubs unique vertical integration model continues to be our foundational strength.





No.1 Australia's largest goat dairy producer

UNIQUE SUPPLY CHAIN MODEL

Our secure supply chain integrating farm to production, provides traceability, scalability and flexibility.

SCALABLE MANUFACTURING

Our secure supply chain integrating farm to production, provides traceability, scalability and flexibility.


UNDERPINNED BY GOAT DAIRY DOMINANCE

Our secure supply chain integrating farm to production, provides traceability, scalability and flexibility.



SPECIALIST LEADER IN AUSTRALIAN GOAT DAIRY

As Australia's largest goat dairy producer, we have now optimised the highest and best use of an exclusive milk source and gained valuable specialist dairy competencies.





ONE BRAND, MULTIPLE FEEDING OCCASIONS

Bubs® caters for all feeding occasions throughout a child's development. Our comprehensive portfolio provides a unique advantage to overcome regulatory hurdles whilst building demand for a sustainable long-term business.



POUCHES



CHINA GENERAL TRADE PORTFOLIO

Provides registered product for physical, direct export to China and opportunity to gain full market access across multi-layered General Trade channel.



In development – not yet registered





川間豆

儿童配方羊奶粉(调制乳粉








STRONG CHINA BRAND REACH & MESSAGING

Leveraging Global Brand Ambassador campaign, through to key opinion leaders and product digital campaign.



Li Xiang

Famous Chinese

Personality

25M Followers

年糕妈妈 Nutritionist, Beijing United Nico Mama Family Healthcare Top Mom & Baby KOL 30M Followers

1M Followers



BUILDING MOMENTUM WITHIN MULTI-LAYERED ECOSYSTEM

Strategic placements in every corner of the Wei Qi board ready to strike. Applying both 'push' and 'pull' strategies to build momentum across China's complex ecosystem, pinpointing the most lucrative channel tiers and demographics, ensuring all paths lead to Bubs[®].



ACCELERATING CBEC CHINA CONSUMER DEMAND

Demonstrating CBEC channel shift & continued strength of brand connection with our end China consumers, as well as positive outcome from our China strategic partnerships with Alibaba and Beingmate.

Chinese consumer demand remains strong, leading into Double 11 Shopping Festival.



*Source: Alibaba, total Tier 1 Platforms Bubs Infant Formula sales. ^Source: Alibaba, Tmall Global Sales Data as at 30 September 2020. **Source: JDI last 30 days total platform sales as at 8 October 2020.



BUBS HOLDS 12% GOAT INFANT FORMULA MARKET SHARE ON TMALL GLOBAL^ +100% market share growth pcp.



MILESTONE ACHIEVEMENT

Ahead of China's top selling Goat infant Nutrition Brand.



SUPPORTING AUSTRALIAN DAIGOU COMMUNITY

Responding to Channel shift towards social commerce, merging live streaming and cross border e-commerce.

Building momentum in new ways to incentivise, stimulate and educate Channel to reactivate sales.



STRONG HOMEBASE IN **AUSTRALIAN FAMILIES AUTHENTIC AUSTRALIAN PROVENANCE IS KEY TO LONG-TERM SUCCESS IN CHINA.**

Despite the recent major disruption to the Australian retail channel due to lack of inbound Daigou retail shoppers, our strong domestic market share growth continues, demonstrating significant and loyal local consumer base across Australian parents.

Bubs Australia was the only manufacturer to achieve double digit sales growth pcp in the last quarter across Australia's top three major grocery and pharmacy retailers combined.¹



Launched in May 2020.

IRI Scan value sales data last 13 weeks as at 27/9/2020 across combined Coles, Woolworths, Chemist Warehouse and My Chemist.
 IRI Scan Units Sold last 13 weeks as at 30/8/2020.



STRATEGIC
FOCUS





OUR CORE **STRATEGIC PRIORITIES**

Since listing, our core strategic focus remains unwavering and has been successfully strengthened in both our core business as well as via extensions into new markets and category growth opportunities.



FOUNDATIONAL BUILDING BLOCKS



CHINA REMAINS OUR KEY FOCUS **LEAD EXPORT MARKET**

China is our primary export market with the highest growth potential for Goat Infant Formula as the fastest growing market segment.



MARKET SIZE

>60%

of the world's Goat Milk Infant Formula is consumed by China, with a majority coming from imported brands.

\$55bn

China is the largest and fastest growing Infant Formula market in the world, valued at >A\$55bn.'

GOAT MILK FORMULA

Goat Milk Formula is expected to grow 20-25% year on year, growing 3x faster than Cow Milk Formula.'

Limited global goat milk supply creates barriers to entry for new market entrants.


~20-25%

x3 faster growth

than Cow Milk

Growth, YoY.

5 year CAGR growth



'Euromonitor 2019 & expert interviews.



UNIQUELY POSITIONED

Bubs[®] is uniquely positioned to capitalise on the premiumisation trend as the only Infant Formula in the world sourced from **Australian goat milk.**








CHINA LARGEST IMF MARKET IN THE WORLD

Goat and Organic Dairy are the two highest growth segments within the China market.

China is largest and fastest growing IMF market



China IMF growth drivers


Penetration: higher adoption of IMF (esp. in low tier cities), driven by increasing disposable income and education on IMF benefits

 $\ensuremath{\text{Per capita consumption}}\xspace$: driven by recognized convenience and nutrition benefits of IMF

Average Selling Price: growth from premiumization

Note: *Also includes sheep, plant and other non-goat IMF products; RMB:USD exchange rate used is 6.5 Source: Euromonitor; Lit research; Expert interview; Analyst reports; Bain analysis

Goat IMF growing 3x faster than traditional IMF




China goat IMF growth drivers

Premiumization: increasing number of premium consumers

Win rate: increasing win / conversion rate vs cow IMF

Average Selling Price: growth in prices from strong demand and constrained supply

Organic Milk IMF Continues High Growth





BARRIERS TO ENTRY FOR CHINA SAMR GENERAL TRADE INCREASING, BUT **STRONG GROWTH OPPORTUNITY REMAINS.**

Regulatory constraints increasing.


China infant formula market is consolidating due to tightening regulations.

- Macro-environment restraining approvals.
 International brands experiencing long lead-times for regulatory approvals.
- Consumer need for trust growing.

Increasing China consumer demand for brands that demonstrate local relevance.

 Growing demand for in-market manufacture.
 Renewed pride in locally manufactured products tailored for Chinese babies.

The Mother and Baby channel provides high growth potential for Bubs® Goat Infant Formula.



Total China Mother & Baby Channel Sales 2018 – 2024° - all category sales.



"CREATED BY BUBS®" PROVIDES CLEAR PATH FOR SAMR ACCESS

Bubs signs MOU with joint venture partner Beingmate to acquire ownership interest in dedicated SAMR brand slot at Beingmate China production facility.

RAPID GROWTH VIA SAMR APPROVED FORMULATION TAILORED FOR CHINESE CONSUMERS. "MADE IN CHINA" FROM 100% BUBS AUSTRALIAN GOAT MILK.



BUBS PENETRATION TO SIGNIFICANTLY EXPAND ACROSS MOTHER & BABY STORES

Bubs to continue to pursue Australian manufactured SAMR approved product.



UNPARALLELED VERTICAL SUPPLY CHAIN EXPERTISE

Provides a strong foundation for long-term "Created by Bubs®" localisation market entry strategy. Due diligence for right to acquire a stakeholding in Beingmate production facility in progress.

> Australia Deloraine Dairy Dandenong South, Victoria

100% OWNERSHIP AUSTRALIAN ORGANIC CERTIFIED AND CHINA FULLY LICENSED DELORAINE MANUFACTURE WITH EXCLUSIVE AUSTRALIAN AND GOAT DAIRY MILK SOURCE. Beingmate Beihai, Guanxi, China

BEINGMATE INFANT FORMULA PLANT DUE DILIGENCE AND LEGAL DOCUMENTATION IN PROGRESS.









BUBS® INFANT FORMULA CHINA PORTFOLIO STRATEGY

Infant Formula to remain our key growth engine and catalyst for maximizing China growth potential.



Concept in development

Segmentation:	PREMIUM	SUPER - PREMIUM	ULTRA - PREMIUM
Regulatory Framework:	FSANZ – English Label	SAMR – China Label	SAMR – China Label
	(Food Standards	(State Administration for	(State Administration for
	Australia New Zealand)	Market Regulation China)	Market Regulation China)
Channel:	Domestic Retail	General Trade	General Trade
	China CBEC	Mother & Baby Stores	Mother & Baby Stores
	Diagou Channel	(Lower Tier Cities)	(Tier 1 Cities)
Place of Manufacture:	Deloraine	Beingmate	Deloraine
	Victoria, Australia	Beihai, China	Victoria, Australia
Indicative Timing:	Existing	In Progress. Aiming for first production CY 2021	In Progress. TBC.




GROWTH PATHWAY

A



LONG TERM SUSTAINABLE GROWTH AGENDA

China remains a critical growth pillar in our 5-year growth horizon.





NUNET

